Guillain-Barré syndrome epidemiology and demographics

Jump to navigation Jump to search

Guillain-Barré syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Guillain-Barré syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Guillain-Barré syndrome epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Guillain-Barré syndrome epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Guillain-Barré syndrome epidemiology and demographics

CDC on Guillain-Barré syndrome epidemiology and demographics

Guillain-Barré syndrome epidemiology and demographics in the news

Blogs on Guillain-Barré syndrome epidemiology and demographics

Directions to Hospitals Treating Guillain-Barré syndrome

Risk calculators and risk factors for Guillain-Barré syndrome epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Priyamvada Singh, MBBS [2]

Overview

Guillain-Barré syndrome (GBS) is an acute, autoimmune, polyradiculoneuropathy affecting the peripheral nervous system, usually triggered by an acute infectious process. The incidence is approximately 1.2 - 3 / 100,000 persons per year across the world. It is commoner in males compared to female and has two peaks (15-35 years and 50-75 years). Incidence is similar across different races.

Epidemiology and Demographics

USA

  • It is the commonest cause of acute, flaccid paralysis in USA.
  • Incidence- 1.2 - 3 / 100,000 persons [1], [2]

International

  • It has been reported all over the world.
  • The incidence is around 1.5 - 3 / 100,000 persons
  • The antecedence of Campylobacter jejuni is commoner in Japan and other Asian countries. Whereas, in American continents and European nations an antecedence of cytomegalovirus is common.

Age

  • Incidence increases with age.
  • Bimodal distribution - First peak during 15 - 35 yrs and second during old age [3].
  • New-borns and infants have the least risks of development of GBS

Races

  • Incidence is similar across different races.

Gender

  • It occurs more commonly in males compared to females. Male to female ratio 1.5:1
  • The incidence has been found to increase post-partum and decreases during pregnancy [4]

References

  1. Day N (1991). "AIDS and insurer discretion". Ohio Medicine : Journal of the Ohio State Medical Association. 87 (5): 226. PMID 1741839. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  2. Romhányi I (1975). "[Letter: The concept of "caucasian race"]". Orvosi Hetilap (in Hungarian). 116 (41): 2449. PMID 1187127. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  3. Prevots DR, Sutter RW (1997). "Assessment of Guillain-Barré syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance". The Journal of Infectious Diseases. 175 Suppl 1: S151–5. PMID 9203708. Retrieved 2012-02-17. Unknown parameter |month= ignored (help)
  4. Jiang GX, de Pedro-Cuesta J, Strigård K, Olsson T, Link H (1996). "Pregnancy and Guillain-Barré syndrome: a nationwide register cohort study". Neuroepidemiology. 15 (4): 192–200. PMID 8817501. |access-date= requires |url= (help)

Template:WH Template:WS